Associated tags: Biotechnology, Pharmaceutical industry, Infection, Candidiasis, Tablet, Patient, FURI, Fungus, Fungemia, IC, FDA, Candida auris, Food, Antimalarial medication, VVC
Biotechnology,
NDA,
Candidiasis,
Tablet,
Antimalarial medication,
VVC,
Patient,
National Medical Products Administration,
NMPA,
Pharmaceutical industry,
Ibrexafungerp In February 2021, SCYNEXIS entered into an agreement for the development and commercialization rights for oral ibrexafungerp in the greater China region with Hansoh Pharma.
Key Points:
- In February 2021, SCYNEXIS entered into an agreement for the development and commercialization rights for oral ibrexafungerp in the greater China region with Hansoh Pharma.
- Under the terms of the agreement, Hansoh is responsible for the development, regulatory approval and commercialization of ibrexafungerp in Greater China.
- Ibrexafungerp, once approved, is expected to become a new, first in class anti-fungal treatment for Chinese patients with vulvovaginal candidiasis (VVC).
- The acceptance of the NDA brings us one more step closer to making this novel and differentiated antifungal available to patients in Greater China.”
Key Points:
- surveillance)
Poster Session 6D: Antifungal drugs & treatment (incl.
- clinical trials)
Poster Session 6D: Antifungal drugs & treatment (incl.
- clinical trials)
Poster Session 6D: Antifungal drugs & treatment (incl.
- clinical trials)
Candidiasis,
Public,
Food and Drug Administration,
Prescription,
Bangladesh Technical Education Board,
Chemistry,
Incidence,
Journal,
Candida auris,
Investment,
Patient,
Body mass index,
Medicines and Healthcare products Regulatory Agency,
3B,
Infection,
Research,
VVC,
Ibrexafungerp,
Diagnosis,
Fungal infection,
FDA,
NIH,
Safety,
Salvage therapy,
Aspergillosis,
GSK,
General Administration of Sport of China,
Biotechnology,
Voriconazole,
Tablet,
Mortality,
Hand,
MHRA,
Journal of Fungi,
SG,
CMC,
IC,
NDA,
Medication,
Case Western Reserve University,
Fungemia,
Antimalarial medication,
United Kingdom,
Poster,
Trial of the century,
Fluconazole,
Food,
Pharmaceutical industry,
Drug,
Self storage,
Cryptocurrency,
Reinsurance,
Fungus,
IQVIA,
FURI GSK will make an upfront payment to SCYNEXIS of $90 million, as well as potential future milestones and tiered royalties.
Key Points:
- GSK will make an upfront payment to SCYNEXIS of $90 million, as well as potential future milestones and tiered royalties.
- JERSEY CITY, N.J., March 31, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the fourth quarter and full year ended on December 31, 2022.
- According to IQVIA data, there were 5,125 total prescriptions for BREXAFEMME written in Q4 2022, and more than 20,000 total prescriptions written in 2022.
- The approval was based on positive results from the pivotal Phase 3 CANDLE study reported in February 2022.
Retrieved on:
Thursday, November 17, 2022
Regulation of food and dietary supplements by the U.S. Food and Drug Administration,
Tablet,
Shanda,
Mycosis,
European Medicines Agency,
WHO,
Public health,
Auris,
Infection,
Food,
Biomedical Advanced Research and Development Authority,
IC,
EMA,
IA,
Biotechnology,
BAA,
Candida auris,
Patient,
QIDP,
Candidiasis,
Broad Agency Announcement,
Aspergillus fumigatus,
FURI,
World Health Organization,
Mucorales,
News,
BID,
Fungemia,
Fungus,
Development,
CBRN,
Canker,
IV,
Drug of last resort,
New Drug Application,
MCM,
PDUFA,
FDA,
Antibiotics,
Pharmaceutical industry For the first time, BARDA announced this week it is seeking partnerships to develop broad-spectrum next-generation antifungal drugs to treat high-priority fungal infections.
Key Points:
- For the first time, BARDA announced this week it is seeking partnerships to develop broad-spectrum next-generation antifungal drugs to treat high-priority fungal infections.
- It is extremely exciting to see BARDA announce increased emphasis on fighting dangerous fungal pathogens, said Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS.
- Ibrexafungerp, with its promising activity against multiple drug resistant and often-deadly fungal infections, has enormous potential to benefit patients with severe fungal disease and limited treatment options.
- In addition, late-stage clinical investigation of oral ibrexafungerp for the treatment of life-threatening invasive fungal infections in hospitalized patients is ongoing.
Retrieved on:
Wednesday, November 9, 2022
BREXAFEMME (ibrexafungerp tablets) prescriptions continued to grow in Q3 2022, increasing 13% over Q2 2022, generating net revenues of $1.6 million in Q3 2022, compared to $1.3 million in Q2 2022.
Key Points:
- BREXAFEMME (ibrexafungerp tablets) prescriptions continued to grow in Q3 2022, increasing 13% over Q2 2022, generating net revenues of $1.6 million in Q3 2022, compared to $1.3 million in Q2 2022.
- JERSEY CITY, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the third quarter ended on September 30, 2022.
- According to IQVIA data, there were 5,785 total prescriptions for BREXAFEMME written in Q3 2022, a 13 percent increase of total prescriptions over Q2 2022.
- BREXAFEMME was prescribed by approximately 2,500 individual healthcare professionals (HCPs) in the third quarter, an increase of 11% over Q2 2022.
VVC,
Public health,
European Medicines Agency,
Regulation of food and dietary supplements by the U.S. Food and Drug Administration,
Mortality,
Research,
Antifungal,
Journal,
IV,
Food,
EMA,
Infection,
Mucorales,
Biotechnology,
Fungemia,
GLOBE,
IA,
FDA,
WHO,
Journal of Fungi,
Tablet,
QIDP,
Review,
Voriconazole,
Immunodeficiency,
PDUFA,
Canker,
NASDAQ,
FURI,
IC,
Patient,
Candidiasis,
Pharmaceutical industry,
Fungus This review in the Journal of Fungi showcases ibrexafungerp as a potential treatment for invasive mold infections, which are a growing threat to public health, particularly in immunocompromised patients, said David Angulo, M.D., Chief Medical Officer of SCYNEXIS and lead author of the publication.
Key Points:
- This review in the Journal of Fungi showcases ibrexafungerp as a potential treatment for invasive mold infections, which are a growing threat to public health, particularly in immunocompromised patients, said David Angulo, M.D., Chief Medical Officer of SCYNEXIS and lead author of the publication.
- In the article, authors describe the need for novel treatment strategies to improve outcomes of difficult-to-treat invasive mold infections, as currently available treatments are limited, resistance against current antifungals is common and mortality remains high.
- Two ongoing clinical trials will provide further insight into the potential of ibrexafungerp for the treatment of invasive mold infections.
- In addition, late-stage clinical investigation of oral ibrexafungerp for the treatment of life-threatening invasive fungal infections in hospitalized patients is ongoing.
